SBIR/STTR Research Award

Metabolic assay utilizing neurodevelopmental cells derived from human pluripotent

Award identifier 6588129944ad2f4134d5ca6c4fad90cff7f892a830518fb9d0eadf57626e21afAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NEWOMICS INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
LMKSNZ862R36
Solicitation number
ES13-003
Topic code
NIEHS

Research abstract

Project Summary/Abstract There is a paradigm shift in testing and modeling of chemical toxicity. Current toxicology calls for human-cell- based (vs. animal-based), evidence-based, and Omics-based assays. Mesenchymal stem cells (MSC) play important roles inthe maintenance and repair of various tissues, including bone, cartilage, and muscle. MSCs are also found in circulating blood and participate in the wound-healing process. Therefore, MSC is arguably one of the most physiologically relevant adult stem cells for chemical toxicology. In response to RFA-ES-13- 003, Newomics Inc. proposes to develop high-throughput Omics-based assays to evaluate the effects of chemical toxicants on proliferation and differentiation of human MSC. The core technology platform will be based on Newomics' breakthrough silicon-microfluidic-chip, the multinozzle emitter array chip (MEA chip), which enables nanoflow liquid chromatography-electrospray ionization mass spectrometry (nanoLC-ESI/MS)- based, high-sensitivity, high-throughput, and multiplex measurements of multiclass analytes (peptides, proteins, and metabolites) at the Omics level, from small volumes of samples. The project will also take advantage of our extensive experience in the characterization of human MSC and mechanistic studies of their responses to genotoxic stresses such as ionizing radiation and chemical toxicants such as hydrogen peroxide. In this Phase I project, we will demonstrate a robust and universal two-stage workflow for Omics-based and high-content screening of chemical toxicity using human MSC. In Aim 1, we will develop phenotypic assays to prioritize the conditions for the focused follow-up Omics-based assays. In Aim 2, we will perform high- throughput proteomic and metabolomic analyses of MSC before andafter chemical treatments, and the associated medium supernatants from each well on the 96-well or 384-well plates used for the quantitative high-throughput screening (qHTS). We will perform bioinformatics analysis and delineate the pathways and networks responsible for the chemical toxicity to MSC. If successful, Newomics' MEA chip may become a universal platform for Omics-based chemical toxicology using stem cells. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Cutting-edge technologies enable breakthroughs in biomedical research. Developments of innovative Omics- based assays for screening chemical toxicity on stem cells will improve risk assessment of personal exposure to environmental toxins, and thereby providing new strategies for public health.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

14 SBIR/STTR records share this UEI (2012–2025). Reported award amounts total $14,707,662. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.